Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ARTV | PRESS-RELEASE | bullish | 7/10 | Artiva reported Q1 2026 GAAP EPS of -$0.95, missing the Street consensus of -$0.84 by 13.1%, while revenue remained $0. | May 8, 2026 |
| ARTV | PRESS-RELEASE | bullish | 7/10 | Artiva Biotherapeutics announced positive initial Phase 2a data for AlloNK in refractory RA, showing 71% ACR50 at six mo | May 8, 2026 |
| PHVS | PRESS-RELEASE | bearish | 6/10 | Pharvaris priced a $115M underwritten offering of 3.87M shares at $29.68 per share, representing ~6% dilution. The capit | May 8, 2026 |
| BIIB | PRESS-RELEASE | bearish | 6/10 | Biogen and Eisai announced a 3-month FDA review extension for the sBLA of LEQEMBI IQLIK (once-weekly subcutaneous inject | May 8, 2026 |
| ODTX | PRESS-RELEASE | neutral | 5/10 | Odyssey Therapeutics priced its upsized IPO of 15.5M shares at $18.00/share, with a concurrent private placement of 1.39 | May 7, 2026 |
| IRD | PRESS-RELEASE | bullish | 6/10 | Opus Genetics reported positive clinical data for its LCA5 gene therapy (OPGx-LCA5) showing over 30-fold improvement in | May 7, 2026 |
| DNLI | PRESS-RELEASE | bullish | 7/10 | Denali reported Q1 2026 EPS of -$0.69, a slight beat vs consensus -$0.71, but the headline is the FDA approval and U.S. | May 7, 2026 |
| SIGA | PRESS-RELEASE | bearish | 6/10 | SIGA reported Q1 2026 total revenues of $6.2M (down 11% YoY) and a net loss of $3.5M vs $0.4M loss a year ago, driven by | May 7, 2026 |
| ANNX | PRESS-RELEASE | bullish | 6/10 | Annexon reported Q1 2026 EPS of -$0.23, beating consensus of -$0.30 by 23%, with net loss narrowing to $44.1M from $54.4 | May 7, 2026 |
| BBIO | PRESS-RELEASE | mixed | 6/10 | BridgeBio reported Q1 2026 revenue of $194.5M (beat $178.6M consensus) driven by $180.6M in Attruby sales, but EPS of -$ | May 7, 2026 |
| VYGR | PRESS-RELEASE | neutral | 4/10 | Voyager Therapeutics reported Q1 2026 EPS of -$0.47, beating consensus of -$0.53 by 11%, but collaboration revenue of $2 | May 7, 2026 |
| TECX | PRESS-RELEASE | neutral | 4/10 | Tectonic Therapeutic reported Q1 2026 EPS of -$1.34, a 44% wider net loss of $25.2M vs -$15.9M a year ago, driven by inc | May 7, 2026 |
| XENE | PRESS-RELEASE | mixed | 6/10 | Xenon Pharmaceuticals reported Q1 2026 net loss of $102.3M ($1.17/share) vs $65.0M ($0.83/share) in Q1 2025, with zero r | May 7, 2026 |
| AMRX | PRESS-RELEASE | bullish | 8/10 | Amneal Pharmaceuticals reported Q1 2026 adjusted EPS of $0.27, beating consensus of $0.17 by 58.8%, and revenue of $723M | May 7, 2026 |
| CLDX | PRESS-RELEASE | mixed | 6/10 | Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and revenue of $15K (miss vs $861K), reflecting wideni | May 7, 2026 |
| INMB | PRESS-RELEASE | mixed | 4/10 | INmune Bio reported Q1 2026 net loss narrowed to $5.4M from $9.7M YoY, but EPS of -$0.20 missed consensus of -$0.18 by 1 | May 7, 2026 |
| ASMB | PRESS-RELEASE | bullish | 6/10 | Assembly Biosciences reported Q1 2026 EPS of -$0.54, beating consensus of -$0.73 by 26%, while collaboration revenue fro | May 7, 2026 |
| CVKD | PRESS-RELEASE | bullish | 6/10 | Cadrenal Therapeutics reported Q1 2026 EPS of -$1.04, beating the -$1.57 consensus by 33.8%. The company also announced | May 7, 2026 |
| QNRX | PRESS-RELEASE | bullish | 6/10 | Quoin Pharmaceuticals reported Q1 2026 loss per ADS of $(1.77), beating consensus of $(2.26), with no revenue. The compa | May 7, 2026 |
| AIM | PRESS-RELEASE | bullish | 6/10 | AIM ImmunoTech announced positive Phase 2 data for Ampligen in recurrent ovarian cancer, showing a 50% objective respons | May 7, 2026 |
| ALXO | PRESS-RELEASE | neutral | 4/10 | ALX Oncology presented exploratory Phase 1b/2 data at ESMO Breast Cancer 2026 showing that evorpacept plus zanidatamab a | May 7, 2026 |
| SLDB | PRESS-RELEASE | bullish | 7/10 | Solid Biosciences dosed the first participant in its Phase 3 IMPACT DUCHENNE trial for SGT-003, a gene therapy for Duche | May 7, 2026 |
| PRME | PRESS-RELEASE | bearish | 5/10 | Prime Medicine reported Q1 2026 EPS of -$0.28, missing consensus of -$0.25 by 12%, and collaboration revenue of $856K ve | May 7, 2026 |
| SPRY | PRESS-RELEASE | neutral | 1/10 | ARS Pharmaceuticals, Inc. announced it will host a conference call on May 15, 2026 to discuss its Q1 2026 results. | May 7, 2026 |
| FLNA | PRESS-RELEASE | neutral | 4/10 | Filana Therapeutics reported Q1 2026 net loss of $0.21 per share, beating consensus of -$0.23 by 8.7%, driven by reduced | May 7, 2026 |
| PRAX | PRESS-RELEASE | bullish | 8/10 | Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68, but the headline i | May 7, 2026 |
| MDWD | PRESS-RELEASE | neutral | 1/10 | MediWound Ltd. announced it will report its Q1 2026 results on May 27, 2026. | May 7, 2026 |
| VCEL | PRESS-RELEASE | bullish | 8/10 | Vericel reported Q1 2026 revenue of $68.4M (+30% YoY) and GAAP EPS of -$0.12 (vs consensus -$0.16, a 25% beat on the los | May 7, 2026 |
| TRDA | PRESS-RELEASE | mixed | 6/10 | Entrada Therapeutics reported Q1 2026 results with a net loss of $39.7M ($0.95/share), beating consensus EPS of -$1.06 b | May 7, 2026 |
| FENC | PRESS-RELEASE | neutral | 1/10 | Fennec Pharmaceuticals Inc. announced it will report its Q1 2026 results on May 14, 2026. | May 7, 2026 |